全文获取类型
收费全文 | 2672篇 |
免费 | 95篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 71篇 |
妇产科学 | 11篇 |
基础医学 | 325篇 |
口腔科学 | 43篇 |
临床医学 | 164篇 |
内科学 | 845篇 |
皮肤病学 | 44篇 |
神经病学 | 192篇 |
特种医学 | 104篇 |
外科学 | 432篇 |
综合类 | 4篇 |
预防医学 | 89篇 |
眼科学 | 53篇 |
药学 | 137篇 |
中国医学 | 1篇 |
肿瘤学 | 263篇 |
出版年
2023年 | 9篇 |
2022年 | 39篇 |
2021年 | 59篇 |
2020年 | 30篇 |
2019年 | 49篇 |
2018年 | 62篇 |
2017年 | 41篇 |
2016年 | 51篇 |
2015年 | 58篇 |
2014年 | 73篇 |
2013年 | 100篇 |
2012年 | 157篇 |
2011年 | 172篇 |
2010年 | 99篇 |
2009年 | 91篇 |
2008年 | 148篇 |
2007年 | 187篇 |
2006年 | 179篇 |
2005年 | 180篇 |
2004年 | 127篇 |
2003年 | 160篇 |
2002年 | 162篇 |
2001年 | 29篇 |
2000年 | 21篇 |
1999年 | 33篇 |
1998年 | 55篇 |
1997年 | 35篇 |
1996年 | 38篇 |
1995年 | 29篇 |
1994年 | 32篇 |
1993年 | 19篇 |
1992年 | 25篇 |
1991年 | 24篇 |
1990年 | 14篇 |
1989年 | 21篇 |
1988年 | 12篇 |
1987年 | 14篇 |
1986年 | 11篇 |
1985年 | 5篇 |
1984年 | 17篇 |
1983年 | 16篇 |
1982年 | 26篇 |
1981年 | 11篇 |
1977年 | 8篇 |
1976年 | 4篇 |
1974年 | 4篇 |
1973年 | 4篇 |
1966年 | 5篇 |
1964年 | 4篇 |
1962年 | 4篇 |
排序方式: 共有2788条查询结果,搜索用时 15 毫秒
31.
T-cadherin (CDH13, H-cadherin) expression downregulated surfactant protein D in bronchioloalveolar cells 总被引:3,自引:0,他引:3
Takeuchi T Misaki A Fujita J Sonobe H Ohtsuki Y 《Virchows Archiv : an international journal of pathology》2001,438(4):370-375
T cadherin is a unique cadherin cell adhesion molecule that is anchored to the surface membrane through a glycosyl phosphatidyl inositol (GPI) moiety. In the present study, we postulated that T cadherin could regulate surfactant protein (SP)-D gene expression in human bronchioloalveolar type-II cells. We transfected A549 cells (human lung cancer cell line with alveolar type-II cell characteristics) with the T-cadherin expression vector. Both original and control plasmid-transfected A549 cells expressed SP-D; however, neither human nor murine T-cadherin-transfected A549 cells expressed SP-D mRNA. The downregulation of SP-D production in human T-cadherin-expressed A549 cells was also demonstrated using Western immunoblotting techniques. Control vector-transfected A549 cells showed a positive band of SP-D but not of T cadherin. In contrast, T-cadherin-transfected A549 cells, which expressed T-cadherin protein, did not produce SP-D. We further examined the relationship of T cadherin and SP-D expression in secondary pulmonary alveolar proteinosis associated with hematolymphoid malignancies. SP-D was detected in bronchioloalveolar type-II cells in alveolar proteinosis. However, little or no T-cadherin expression was detected in alveolar type-II cells in these patients. To our knowledge, this is the first report describing an effect of cadherin on SP production in bronchioloalveolar cells. 相似文献
32.
Nobuhito Kishimoto Hisako Ohnishi Jiro Fujita Tadashi Kamei Shinya Tada Nobuo Ueda 《Arerugī》2004,53(4):417-422
Inhaled beta(2)-agonists (long-acting as well as short acting) are used world-wide for the relief of asthma symptoms. However, there are few reports which have evaluated the additive effect of short-acting beta(2)-agonists to long-acting beta(2)-agonists on airway resistance measured by a plethysmography. This study was designed to evaluate the additive effect of inhaled short-acting beta(2)-agonists (protecarol) to long-acting beta(2)-agonists (salmeterol) on airway resistance in normal healthy volunteers (S+P group). In addition, to compare the effects of beta(2)-agonists which have different types of intrinsic activities, acute effect of inhaled procaterol adding to procaterol was also evaluated (P+P group). Seven healthy volunteers (all male and all non-smokers) were entered in this study. Pulmonary function was measured by a body plethysmography. Forced expiratory volume per 1 second (FEV1), the maximum flow rate at 25% (V(.) 25), the maximum flow rate at 50% of forced vital capacity (V(.) 50), and airway resistance were measured before and after inhalation of salmeterol (1 dry powder, 50 microg) or procaterol (2 puffs, 20 microg). Sixty minutes after inhalation of salmeterol, or 15 minutes after inhalation of procaterol, inhalation of procaterol (2 puffs, 20 microg) was added, and then pulmonary function was monitored. FEV1, V(.) 25, and V(.) 50 were significantly increased after inhalation of salmeterol as well as procaterol. In addition, airway resistance decreased significantly after inhalation of salmeterol as well as procaterol. In the S+P group, additional decrease of airway resistance after inhalation of procaterol was relatively small compared with the P+P group. In conclusion, although additional bronchodilatoric effects were observed in the S+P and P+P group, the effects seemed to be different based on the intrinsic activity of each beta(2)-agonist. 相似文献
33.
Absence of either gastric or intestinal phenotype in microscopic differentiated gastric carcinomas 总被引:6,自引:0,他引:6
Kawachi H Takizawa T Eishi Y Shimizu S Kumagai J Funata N Koike M 《The Journal of pathology》2003,199(4):436-446
Differentiated gastric carcinoma (DGC) corresponds roughly to the intestinal type of gastric carcinoma described by Laurén. It has been suggested that DGCs arise from intestinalized gastric mucosa, but recent findings regarding their mucin expression do not support this hypothesis. To evaluate the histogenetic relationship between DGCs and intestinal metaplasia, lesions that are as small as possible should be examined. Twenty-five DGCs, ranging in their greatest dimension from 0.4 to 2.7 mm, were collected and divided into two groups by size. Group A consisted of 13 lesions less than 1.4 mm across, and group B of 12 lesions 1.4 mm or more. The presence of mucin and a brush border was assessed by immunostaining with antibodies against human gastric mucin, pyloric-gland-type mucin, Muc-2 glycoprotein, and CD10 antigen, and the lesions were classified as having the gastric phenotype (G-type), intestinal phenotype (I-type), mixed gastric and intestinal phenotype (M-type), or null phenotype (N-type). Thirteen (52%) of the 25 lesions were N-type, 5 (20%) lesions were G-type, 5 (20%) were I-type, and 2 (8%) were M-type. Group A had a larger proportion of N-type lesions than B (10/13, or 77%, vs. 3/12, or 25%; p = 0.027, chi-square test for proportions). Group B had a larger proportion of G-type lesions than A (5/12, or 42%, vs. 0/13, or 0%; p = 0.033). The phenotypes of the carcinomas and their surrounding mucosa were unrelated. Therefore, DGCs may arise from gastric mucosa affected by intestinal metaplasia or not, without having either the gastric or intestinal phenotype. 相似文献
34.
Takuma Narita Shingo Hatakeyama Shintaro Narita Masahiro Takahashi Toshihiko Sakurai Sadafumi Kawamura Senji Hoshi Jiro Shimoda Toshiaki Kawaguchi Shigeto Ishidoya Koji Mitsuzuka Yoichi Arai Akihiro Ito Norihiko Tsuchiya Tomonori Habuchi Chikara Ohyama 《Translational andrology and urology》2021,10(1):417
BackgroundThe clinical benefit of the combined androgen blockade (CAB) therapy over luteinizing hormone-releasing hormone analog (LH-RHa) monotherapy for hormone naïve metastatic prostate cancer (mHNPC) is unclear. Therefore, we retrospectively compare the effectiveness of CAB with the LH-RHa monotherapy on the prognosis of Japanese patients with mHNPC.MethodsWe retrospectively evaluated the prognosis of 517 patients diagnosed with mHNPC between August 2001 and May 2017. The patients’ data were obtained from the Michinoku Urological Cancer Research Group database and Hirosaki University-related hospitals. Patients were divided into the CAB and LH-RHa monotherapy groups based on primary androgen deprivation therapy (ADT). Overall survival (OS), cancer-specific survival (CSS), and castrate-resistant prostate cancer-free survival (CRPC-FS) were compared between the two groups using the Kaplan-Meier curve analysis. Inverse probability of treatment weighting (IPTW)-adjusted Cox hazard proportional analyses was performed to investigate the effect of primary ADT on oncological outcomes.ResultsThe median age was 73 years old. The numbers of patients in the CAB and LH-RHa monotherapy groups were 447 and 70, respectively. The Kaplan-Meier curve analysis showed no significant differences in either 5-year OS (56.7% vs. 52.5%, P=0.277), CSS (61.1% vs. 56.4%, P=0.400), and CRPC-FS (33.1% vs. 31.1%, P=0.529) between the groups. IPTW-adjusted multivariate Cox hazard proportional analyses showed no significant differences in OS, CSS, and CRPC-FS between the two groups.ConclusionsNo significant differences in oncological outcomes were observed between the CAB and LH-RHa monotherapy groups in patients with mHNPC. 相似文献
35.
Karube Y Katsuno K Ito S Matsunaga K Takata J Kuroki M Murakami M Matsuoka Y 《Annals of nuclear medicine》1999,13(6):407-413
The method for subtracting the initial image from the localization image was evaluated for radioimmunoscintigraphy of tumors with technetium-99m (Tc-99m) labeled antibodies. Monoclonal antibodies were parental mouse and mouse-human chimeric antibodies to carcinoembryonic antigen (CEA), designated F11-39 and ChF11-39, respectively, both of which have been found to discriminate CEA in tumor tissues from the CEA-related antigens. After reduction of the intrinsic disulfide bonds, these antibodies were labeled with Tc-99m. In vivo studies were performed on athymic nude mice bearing the human CEA-producing gastric carcinoma xenografts. Though biodistribution results showed selective and progressive accumulation of Tc-99m labeled antibodies at the tumor site, high radioactivity in blood was inappropriate for scintigraphic visualization of the tumors within a few hours. We examined the subtraction of the initial Tc-99m image from the Tc-99m localization image after a few hours. Subtracted images of the same count reflected the in vivo behavior of the Tc-99m radioactivity. The subtracted scintigrams revealed excellent tumor images with no significant extrarenal background. Visualization of the tumor site was dependent on antigen-specific binding and nonspecific exudation. These results demonstrate that a method of subtraction of the initial image may serve as a potentially useful diagnostic method for an abnormal site for agents with a low pharmacokinetic value. 相似文献
36.
(Received for publication on Dec. 8, 1997; accepted on July 7, 1998) 相似文献
37.
Radiotherapy of Vertebral Hemangiomas 总被引:2,自引:0,他引:2
Koh-Ichi Sakata Masato Hareyama Atushi Oouchi Mitsuo Sido Hisayasu Nagakura Mituharu Tamakawa Hidenari Akiba Kazuo Morita 《Acta oncologica (Stockholm, Sweden)》1997,36(7):719-724
Between 1975 and 1996, 14 patients (11 females, 3 males) with vertebral hemangioma received treatment with radiotherapy. Thirteen patients had a history of back pain or lumbago and 2 patients had neurological symptoms such as sensory impairment or paraplegia. The standard dose administered was 36 Gy in 18 fractions (five treatments per week). In the 13 patients with pain, this was completely or partially relieved. The condition of a man with hypesthesia of the legs deteriorated and a woman with paraplegia who was treated with decompressive laminectomy followed by radiotherapy recovered completely after irradiation. CT scan before irradiation showed thickened trabeculae as small punctate areas of sclerosis in all patients. At MR imaging before irradiation, T2-weighted MR images showed areas of high intensity in all patients and MR images demonstrated lesion enhancement. However, none of the patients who were treated successfully with radiation demonstrated any changes of the affected vertebra in the conventional radiographic films, CT scan or MR imaging, even 5 years after irradiation. Radiological imaging is indispensable for the diagnosis of vertebral hemangiomas but does not appear to be useful for evaluating the effects of radiotherapy. 相似文献
38.
39.
Nationwide survey on complementary and alternative medicine in cancer patients in Japan. 总被引:1,自引:0,他引:1
Ichinosuke Hyodo Noriko Amano Kenji Eguchi Masaru Narabayashi Jiro Imanishi Midori Hirai Tomohito Nakano Shigemitsu Takashima 《Journal of clinical oncology》2005,23(12):2645-2654
PURPOSE: To determine the prevalence of use of complementary and alternative medicine (CAM) by patients with cancer in Japan, and to compare the characteristics of CAM users and CAM nonusers. PATIENTS AND METHODS: A questionnaire on cancer CAM and the Hospital Anxiety and Depression Scale were delivered to 6,607 patients who were treated in 16 cancer centers and 40 palliative care units. RESULTS: There were 3,461 available replies for a response rate of 52.4%. The prevalence of CAM use was 44.6% (1,382 of 3,100) in cancer patients and 25.5% (92 of 361) in noncancer patients with benign tumors. Multiple logistic regression analysis determined that history of chemotherapy, institute (palliative care units), higher education, an altered outlook on life after cancer diagnosis, primary cancer site, and younger age were strongly associated with CAM use in cancer patients. Most of the CAM users with cancer (96.2%) used products such as mushrooms, herbs, and shark cartilage. The motivation for most CAM use was recommendation from family members or friends (77.7%) rather than personal choice (23.3%). Positive effects were experienced by 24.3% of CAM users with cancer, although all of them received conventional cancer therapy concurrently. Adverse reactions were reported by 5.3% of cancer patients. CAM products were used without sufficient information by 57.3% of users with cancer and without a consultation with a doctor by 60.7% of users. CONCLUSION: This survey revealed a high prevalence of CAM use among cancer patients, without sufficient information or consultation with their physicians. Oncologists should not ignore the CAM products used by their patients because of a lack of proven efficacy and safety. 相似文献
40.